XNCR — Xencor Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1326732 ·
Last close
$34.50
Market Cap
$2.59B
52W High
$40.60
52W Low
$10.38
ADV30
1,677,504
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 116,520,000 — 22,864,000 39,436,000 770,505,000 59,622,000 210,070,000
Jun 2026 51,221,000 — -37,068,000 -21,729,000 724,960,000 44,663,000 221,732,000
Mar 2026 4,516,000 — -77,862,000 -128,916,000 736,846,000 14,170,000 221,213,000
Dec 2025 28,237,000 — -53,628,000 -6,653,000 875,495,000 54,073,000 239,908,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-172,355,000
Investing CF
$190,298,000
Financing CF
$18,293,000
CapEx
$-4,092,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-907,168,000
Inventory
—
Receivables
$64,837,000
ST Investments
$345,457,000
EBIT TTM
$-92,040,000
Pretax Income TTM
$-115,560,000
Interest Exp TTM
$23,520,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$200,494,000
EBITDA
$-135,872,000
Free Cash Flow
$-96,220,752
Enterprise Value
$2,437,816,832
Total Cash
$405,079,008
Total Debt
$160,227,008
Shares Out
75,039,689
Trailing EPS
$-1.56
Book Value
$7.50
ROE
-19.9%
ROA
-11.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 125,576,000 -177,502,000 -91,923,000 875,495,000 239,908,000 635,587,000 -135,117,000
Dec 2024 110,493,000 -178,408,000 -232,618,000 951,945,000 277,919,000 677,611,000 -202,188,000
Dec 2023 174,615,000 -132,362,000 -133,133,000 965,135,000 303,048,000 661,750,000 -77,926,000
Dec 2022 164,579,000 -82,473,000 -55,181,000 846,266,000 118,770,000 727,496,000 24,485,000

TTM Snapshot

Revenues TTM
$104,973,000
NetIncome TTM
$-163,325,000
OpCashFlow TTM
—
Assets (Latest)
$724,960,000
Forward EPS
$-3.54

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $22.50 · spot: $34.39 · call volume: 274 · put volume: 27
Expected Move to 2027-02-19: ±$11.00 (31.99%) — implied range $23.39 – $45.39 · ATM straddle on $35.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MBX MBX Biosciences, Inc. $2.64B $53.10 —
IDYA IDEAYA Biosciences, Inc. $2.65B $27.40 —
HCM HUTCHMED (China) Ltd $2.50B $14.40 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —
NAMS NewAmsterdam Pharma Co N.V. $2.33B $19.39 —

News headlines (Yahoo Finance, 1h cache)

Early Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)
2026-11-12 09:11 · Yahoo
Xencor (XNCR) Stock Trades At A Premium To Its Sales
2026-11-05 07:19 · Yahoo
Xencor: Q3 Earnings Snapshot
2026-11-04 21:26 · Yahoo
Xencor Reports Third Quarter 2026 Financial Results
2026-11-04 21:01 · Yahoo
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
2026-10-27 15:51 · Yahoo
Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
2026-10-26 22:21 · Yahoo
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
2026-10-26 20:13 · Yahoo
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
2026-10-26 19:02 · Yahoo
Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
2026-10-26 18:55 · Yahoo
Xencor shares jump as kidney cancer drug data support Phase 3 plans
2026-10-26 16:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.